01—Abstract
Summary
Summary of the 10-Q filed May 7, 2025. Cited figures are marked; the original filing is the authoritative source.
Beigene, Ltd. (ONC) demonstrated a significant financial turnaround in the first quarter of 2025, reporting GAAP net income of $1.27 milliona compared to a net loss of $251.15 million in the prior year period.
This improvement was driven by a substantial 48.6% increase in total revenues to $1.12 billionb, primarily fueled by a 48.4% surge in product revenue to $1.11 billion. The company's flagship product, BRUKINSA®, saw a remarkable 62.1% increase in global sales, reaching $791.7 million, and now leads in new patient starts and market share in the U.S. for BTKi. Despite the revenue growth and return to profitability, operating expenses, particularly research and development, saw a modest increase of 4.6% to $481.9 million, and selling, general, and administrative expenses increased by 7.5% to $459.3 million, reflecting continued investment in pipeline advancement and commercial expansion.
The company ended the quarter with a strong liquidity position, holding $2.53 billionc in cash, cash equivalents, and restricted cash, while successfully reducing its total debt. The strategic focus on expanding its oncology pipeline, coupled with positive sales momentum for its key products, positions Beigene for continued growth.
02—Key points
Key Highlights
- Total revenues increased by 48.6% to $1.12 billion for the three months ended March 31, 2025, compared to $751.7 million in the prior-year period.
- Net product revenue grew by 48.4% to $1.11 billion, driven by strong performance across key products.
- BRUKINSA® global sales increased by 62.1% to $791.7 million, reflecting continued demand and market share gains.
- The company achieved GAAP net income of $1.27 million, a significant improvement from a net loss of $251.15 million in the same period last year.
- Operating expenses increased by 6.0% to $941.2 million, with R&D expenses up 4.6% to $481.9 million and SG&A expenses up 7.5% to $459.3 million.
- Cash, cash equivalents, and restricted cash stood at $2.53 billion as of March 31, 2025.
- The company announced shareholder approval to rename itself BeOne Medicines Ltd. and redomicile to Switzerland.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, BeOne Medicines Ltd. kept $0.00.
- Revenue$1.12B100.0%
- Cost of revenue−$165.0M14.8%
- Gross profit$952.3M85.2%
- Operating costs−$941.2M84.2%
- Operating income$11.1M1.0%
- Interest, other & tax−$9.8M0.9%
- Net income$1.3M0.1%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 7, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $1.12B$751.65M | +48.6% |
| Gross Profit | $952.28M$626.72M | +51.9% |
| R&D Expenses | $481.89M$460.64M | +4.6% |
| SG&A Expenses | $459.29M$427.43M | +7.5% |
| Operating Expenses | $941.17M$888.07M | +6.0% |
| Operating Income | $11.10M-$261.35M | +104.2% |
| Interest Expense | $12.96M$12.40M | +4.5% |
| Net Income | $1.27M-$251.15M | +100.5% |
| Shares Outstanding (Basic) | 1.39B1.36B | +2.5% |
| Shares Outstanding (Diluted) | 1.45B1.36B | +6.6% |
05—Questions
Frequently Asked Questions
What is the primary driver behind the company's significant revenue growth in Q1 2025?
The primary driver of Beigene's revenue growth in Q1 2025 is the strong performance of its product sales, particularly BRUKINSA®, which saw a 62.1% increase in global sales. This growth is also supported by increased sales of TEVIMBRA® and in-licensed products from Amgen.
How has the company's profitability changed compared to the previous year?
Beigene has returned to profitability in Q1 2025, reporting a GAAP net income of $1.27 million, a substantial improvement from the net loss of $251.15 million recorded in Q1 2024. This swing to profitability is a key positive development for investors.
What is the company's current cash position and debt level?
As of March 31, 2025, Beigene maintained a strong liquidity position with $2.53 billion in cash, cash equivalents, and restricted cash. The company also reported a total debt of $923.6 million, having repaid $97.1 million of debt in the first quarter.
What are the significant developments announced by the company during the quarter?
Key developments include shareholder approval to rename the company to BeOne Medicines Ltd. and redomicile to Switzerland. Additionally, the company announced a favorable U.S. Patent Office decision invalidating claims in a patent challenged by Beigene, and the discontinuation of the clinical development program for ociperlimab.
06—Continue